welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
UT researcher, with CureDuchenne support, launches company to treat DMD using CRISPR/Cas9 technology
Eric Olson, a molecular biologist, has spent more than half his life in the lab. Now, the 62-year-old University of Texas researcher and distinguished professor is a businessman as well.
Olson, director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine in Dallas, has teamed up with the nonprofit group CureDuchenne — through its investment arm — to form Exonics Therapeutics.
The new company, based in Cambridge, Massachusetts, will use the CRISPR/Cas9 gene-editing technique known as SingleCut with the aim of correcting up to 80 percent of the 3,000 mutations that cause Duchenne muscular dystrophy (DMD).
rareRelated
-
Upgrading the toolbox for Duchenne muscular dystrophy research with a new rabbit modelResearch to improve our understanding of...
-
Gene Editing CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=8xNh1qr4...
-
Development of a CRISPR-based gene therapy approach targeting the large exon 45-exon 55 mutation hotspot in DMD geneGene replacement and exon skipping thera...
-
U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editingA U.S. appeals court on Monday allowed a...
-
Why my patient advocacy organization is investing in CRISPRIn last year’s action film “Rampage,...
-
Dr. Eric Olson CRISPR/Cas9 Presentation at CureDuchenne Careshttps://www.youtube.com/watch?v=P-Q8HFXk...
-
The Gene-Edited Babies And CRISPR-Cas9 Controversy, ExplainedOutrage continues to grow over the news ...
